Advertisement


Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

ESMO Congress 2022

Advertisement

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Dear colleagues, it's my pleasure to talk to you about two abstracts that we have reviewed here which have been presented at the ESMO meeting. It's about immunotherapy in patients with advanced non-small cell lung cancer. The first one was an update of a very important trial, the EMPOWER-Lung 1 trial, comparing a monotherapy with a checkpoint inhibitor, cemiplimab, against platinum-based chemotherapy. We have seen that with an update of the follow-up of the [inaudible 00:00:37] signal and efficacy, we do see the benefit in progression-free survivor and overall survival. There was an interesting part on this trial, because those patients who progressed after immunotherapy had the opportunity to get a combination of a continuation with cemiplimab and a chemotherapy. These data also were resent presented. 64 patients did receive the combination of the chemotherapy and the immunotherapy. The efficacy data were quite impressive, but we have to be aware this was an exploratory analysis for a limited number of patients. We do need more information on the post-progression therapy, but this is certainly something that we need to take into account for our future therapies. We need more prospective data, like the INSIGNIA trial, determining the role of the monotherapy of the combination. But this has been a very interesting update. The second trial was a French trial. In this trial, the colleagues investigated the role of treatment discontinuation after a certain time of therapy. Patients with an advanced non-small cell lung cancer were treated with a combination of nivolumab and ipilimumab for 6 months, and if there was a response or a treatment stabilization, the patient were randomized in one arm to continue the immunotherapy combination until disease progression or treatment was discontinued, the treatment was stopped. The patients were observed and were monitored, and at the event of progression, there was the opportunity for a reposition to the immunotherapy combination. This was a very well-designed, non-inferiority trial. Unfortunately, recruitment could not be completed due to external circumstances. Only 71 patients were randomized. So we only have exploratory results coming out of this trial, but we did see that there was no detrimental effect seen in the patient who stopped after 6 months of immunotherapy. In contrast, there was a numerical improvement of progression-free survival in those group of patients, there was no difference in overall survival, and as expected, tolerability was much better in the group of patients who discontinued the therapy after 6 months. In summary, we have got an update on a very important trial, one of the monoimmunotherapy trials investigating cemiplimab. We do see a confirmation of the efficacy with the longer follow up, we have seen a very exploratory signal on post-progression treatment opportunities, and we have a new idea that we might discontinue immunotherapy in responding patients after a certain time of therapy, and this is something which is now going to be investigated in ongoing perspective trials.

Related Videos

Skin Cancer
Immunotherapy

Sapna P. Patel, MD, on Melanoma: New Data on Pembrolizumab, Adjuvant vs Neoadjuvant Plus Adjuvant

Sapna P. Patel, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the SWOG S1801 trial, which showed that using single-agent pembrolizumab as neoadjuvant therapy improved event-free survival compared to adjuvant therapy in high-risk resectable stage III–IV melanoma (Abstract LBA6).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.

Skin Cancer

John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab

John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1 treatment. Around 50% of TIL-treated patients had a response, and 20% had a complete response (Abstract LBA3).

Lung Cancer

Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution

Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).

Advertisement

Advertisement




Advertisement